Declaration of Competing Interest statements were not included in the published version of the following articles that appeared in previous issues of Journal of Clinical & Translational Endocrinology.
The appropriate Declaration/Competing Interest statements, provided by the Authors, are included below.
1) Finding the clinical utility of 1,5-anhydroglucitol among primary care practitioners (Journal of Clinical & Translational Endocrinology, 2020; 20C: 100224) https://doi.org/10.1016/j.jcte.2020.100224
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: CPV Technologies, LLC, owns the intellectual property used to prepare the cases and QURE, LLC collected the data. This study was funded by GlycoMark, Inc., New York, NY. Otherwise, there are no conflicts to disclose.
2) Prevalence of prediabetes and type 2 diabetes in two non-random populations aged 44–77 years in the Faroe Islands (Journal of Clinical & Translational Endocrinology, 2019; 16C: 100187) https://doi.org/10.1016/j.jcte.2019.100187
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: CPV Technologies, LLC, owns the intellectual property used to prepare the cases and QURE, LLC collected the data. This study was funded by GlycoMark, Inc., New York, NY. Otherwise, there are no conflicts to disclose.
3) High frequency of empty sella, with gender differences, in the early neuroradiology evaluation of patients with traumatic brain injury. A prospective study (Journal of Clinical & Translational Endocrinology, 2019; 15C: 179) https://doi.org/10.1016/j.jcte.2018.12.008
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: CPV Technologies, LLC, owns the intellectual property used to prepare the cases and QURE, LLC collected the data. This study was funded by GlycoMark, Inc., New York, NY. Otherwise, there are no conflicts to disclose.
4) Study of Epstein–Barr virus serological profile in Egyptian patients with Hashimoto thyroiditis: A case-control study (Journal of Clinical & Translational Endocrinology, 2020; 20C: 100222) https://doi.org/10.1016/j.jcte.2020.100222
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: CPV Technologies, LLC, owns the intellectual property used to prepare the cases and QURE, LLC collected the data. This study was funded by GlycoMark, Inc., New York, NY. Otherwise, there are no conflicts to disclose.
5) Impact of vitamin D treatment on 25 hydroxy vitamin D levels and insulin homeostasis in obese African American adolescents in a randomized trial (Journal of Clinical & Translational Endocrinology, 2018; 12C: 145) https://doi.org/10.1016/j.jcte.2018.03.002
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: CPV Technologies, LLC, owns the intellectual property used to prepare the cases and QURE, LLC collected the data. This study was funded by GlycoMark, Inc., New York, NY. Otherwise, there are no conflicts to disclose.
6) Attitudes and habits of patients with type 1 diabetes during fasting Ramadan (Journal of Clinical & Translational Endocrinology, 2018; 14C: 159) https://doi.org/10.1016/j.jcte.2018.09.001
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: CPV Technologies, LLC, owns the intellectual property used to prepare the cases and QURE, LLC collected the data. This study was funded by GlycoMark, Inc., New York, NY. Otherwise, there are no conflicts to disclose.
7) Hypoglycemic symptoms in the absence of diabetes: Pilot evidence of clinical hypoglycemia in young women (Journal of Clinical & Translational Endocrinology, 2019; 18C: 100202) https://doi.org/10.1016/j.jcte.2019.100202
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: CPV Technologies, LLC, owns the intellectual property used to prepare the cases and QURE, LLC collected the data. This study was funded by GlycoMark, Inc., New York, NY. Otherwise, there are no conflicts to disclose.
8) Effects of gender affirming hormone therapy on body mass index in transgender individuals: A longitudinal cohort study (Journal of Clinical & Translational Endocrinology, 2020; 21C: 100230) https://doi.org/10.1016/j.jcte.2020.100230
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: CPV Technologies, LLC, owns the intellectual property used to prepare the cases and QURE, LLC collected the data. This study was funded by GlycoMark, Inc., New York, NY. Otherwise, there are no conflicts to disclose.
9) Bimodal glucose distribution in Asian Indian pregnant women: Relevance in gestational diabetes mellitus diagnosis (Journal of Clinical & Translational Endocrinology, 2018; 13C: 155) https://doi.org/10.1016/j.jcte.2018.06.001
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: CPV Technologies, LLC, owns the intellectual property used to prepare the cases and QURE, LLC collected the data. This study was funded by GlycoMark, Inc., New York, NY. Otherwise, there are no conflicts to disclose.
10) Bimodal distribution of fasting, one and two hour post load plasma glucose in Asian Indian pregnant women without pre-gestational diabetes: Gestational age related changes (Journal of Clinical & Translational Endocrinology, 2019; 16C: 100195) https://doi.org/10.1016/j.jcte.2019.100195
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: CPV Technologies, LLC, owns the intellectual property used to prepare the cases and QURE, LLC collected the data. This study was funded by GlycoMark, Inc., New York, NY. Otherwise, there are no conflicts to disclose.